POP Biotechnologies Vaccine Technology to Enter Phase III Clinical Studies as Part of Eubiologics' COVID-19 Vaccine Candidate, EuCorVac-19
Feb 7, 2022
POP Biotechnologies (POP BIO), a biopharmaceutical startup, announces the approval of the plan for a Phase 3 clinical study of EuCorVac-19, a COVID-19 vaccine candidate developed by South Korean partner EuBiologics (KOSDAQ: 206650, CEO, Dr. Baik YoungOk, Mr. Seukkeun Choi) from the Ministry of Food and Drug Safety in South Korea. EuCorVac-19 is a protein-based vaccine consisting of Eubiologics' protein antigen, EulMT, in-licensed from Korea Institute of Science and Technology and the Spontaneous-Nanoliposome Antigen Particle (SNAP) technology of POP BIO. "This Phase III trial is a monumental step forward for our technology. Achieving this critical milestone provides validation towards not only solving this unprecedented global crisis but also provides invaluable support towards our platform's development, further enabling the creation of new vaccines with tremendous potential to alleviate suffering worldwide," says POP BIO President and cofounder Jonathan Smyth.
POP BIO's Spontaneous Nanoliposome Antigen Particleization (SNAP) technology enables the rapid development and manufacturing of highly immunogenic particle-based vaccines and immunotherapies directed against infectious disease and cancer through a cobalt modified variant of the PoP technology (CoPoP). The SNAP technology enables the stable particle-formation and liposome-display of protein and peptide antigens, resulting in substantial improvements in immune responses. According to Dr. Jonathan Lovell, technology inventor and POP BIO co-founder, "SNAP is a vaccine platform technology that could be applicable to any vaccine-related indication, for both chronic and infectious diseases. In-human testing for the COVID-19 vaccine will de-risk the technology for many other indications."
Eubiologics will be able to commence Phase III comparison trials for 4,000 healthy participants in the Philippines, Bangladesh, and other countries based on a standard comparison clinical trial guideline. Eubiologics will work closely with international research organizations for expedited recruitment in countries with low vaccination rates as well as the analysis of trial results to accelerate the regulatory approval and commercialization of EuCorVac-19. EuCorVac-19 has already proved its safety and efficacy in Phase I/II clinical trials, the results of which were announced in December 2021. Eubiologics expects to expedite the development of an Omicron variant vaccine based on the same platform used for EuCorVac-19. A company official said, "The company has already had product supply MOUs with partners in the Philippines and Saudi Arabia, and many Asian, CIS, Latin American partners have shown a great interest in EuCorVac-19. Once the product is launched, the company will target the overseas markets that have high population and middle-income based on the product's safety, efficacy, and logistics convenience."
POP BIO is a privately held biotechnology company focused on the research and development of novel therapeutics and vaccines employing their proprietary porphyrin-phospholipid (PoP) liposome technologies. The PoP technology is exclusively licensed from the SUNY-RF.
Eubiologics is a South Korean Biotechnology company that received funds for the Phase I/II EuCorVac-19 trial from the new drug development committee of the Korean Ministry of Health and Welfare and recently submitted the application for phase III trial to get additional financial assistance. Eubiologics has two main animal-based bioreactors (1,000L) to produce recombinant protein antigens at Chuncheon Plant 1 and EcML which is adjuvant at Chuncheon Plant 2. The total capacity of the COVID-19 vaccine is from 100M to 200M doses per year. EuCorVac-19 vaccine uses the same type of cell line, which is for antibody treatment, so if the company uses these facilities, its manufacturing capacity can be further expanded.
For more information, contact: [email protected]
Press Release Service by Newswire.com
Original Source: POP Biotechnologies Vaccine Technology to Enter Phase III Clinical Studies as Part of Eubiologics' COVID-19 Vaccine Candidate, EuCorVac-19
More News
U.S. Bond Yields Hit Highest Level Since 2002
The higher yields, which are pressuring consumer and corporate borrowers and increasingly weighing on certain corners of the stock market, are unlikely to dissipate soon.
Trump’s Threat to Ban Diesel Exports Sets Off Global Alarms
A reduction in refineries has already driven the price of diesel to record highs, threatening economies. An U.S. export ban would be “tremendous shock and blow.”
PM warned Rosebank oil field could breach West Bank sanctions
Campaigners and Green Party leader Zack Polanski raise concerns about Rosebank's ties to an Israeli firm.
HMRC urged to scrutinise tax implications of Man City case
The Treasury Committee, which is responsible for overseeing HMRC, has urged the body to scrutinise tax implications of the Manchester City verdict.
As Mortgage Rates Hit Highest Level Since 2023, Buyers Look at ARMs
The average 30-year, fixed-rate home loan rose to 7.28 percent, up from 6.34 percent a year ago. More buyers are now turning to adjustable-rate mortgages.
Thames Water apologises after £145,000 customer billing mistake
The firm has apologised to the family.
Help! Air Canada Got Me to Europe, Then Stranded Me There.
The airline helpfully rebooked a delayed traveler from Toronto, but failed to mention it had also canceled her return trip. She spent $800 to get home.
Travelodge failed sex assault victim 'at every stage'
Room intrusions were still being reported at one-in-10 Travelodge hotels this summer, a review finds.
Swedish Company Uses A.I. Likeness of Greta Garbo in Ad
An ad produced by the manufacturing company SKF Group featured a digital version of the Swedish American actress, who died in 1990. Not all viewers found the replica convincing.
'We must keep going' says charity hit by fuel prices
Both petrol and diesel prices have risen by a third or more in just the past seven months.
Is it time to ditch premium bonds?
Martin Lewis says though they are the UK's most popular form of savings, not everybody benefits from them. Martin explains who premium bonds are best for, and who they aren’t so good for.
Federal Watchdog Investigates Adam Kinzinger for Kalshi Bets on His Pardon
The inquiry by the Commodity Futures Trading Commission centers on bets the former congressman made on Kalshi in the weeks before he was pardoned in January 2025.
YOUR NEWS, OUR NETWORK.
Do you have Great News you want to tell the world?
Be it updates about your business or your community, you can make sure that it’s heard by submitting your story to our network reaching hundreds of news sites across 6 verticals.